$1.43
-3.5%Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Chief People Officer
Strategic Advisor
Compensation
$201,676
During the last 12 months, insiders have purchased $172K and sold $946K worth of LITS shares, resulting in $775K of net selling activity.
0
0.00
0
0.00
+0
+$0
70.0K
97.70K
690.6K
946.14K
-848K
-$848K
32.1K
73.81K
0
0.00
+74K
+$74K
0
0.00
0
0.00
+0
+$0
Flynn James P
Director
$146K
Lee Charles Benjamin
Director
$26K
Schornstein Alexander
10 Percent Owner
$946K
Strong bearish signal with $775K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
2 insider buyers vs. 1 sellers. More insiders buying than selling indicates positive sentiment.
LITS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | December 30, 2025 | December 30, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | December 20, 2024 | December 20, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | November 08, 2023 | November 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | October 27, 2022 | December 06, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | October 28, 2021 | December 16, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | October 27, 2020 | December 16, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | October 23, 2019 | December 05, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | October 11, 2018 | November 29, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | October 16, 2017 | November 30, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | October 17, 2016 | December 01, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.